Omnicell, Inc. (NASDAQ:OMCL) Stock Holdings Reduced by Yousif Capital Management LLC

Yousif Capital Management LLC lowered its stake in Omnicell, Inc. (NASDAQ:OMCL) by 2.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,413 shares of the company’s stock after selling 426 shares during the period. Yousif Capital Management LLC’s holdings in Omnicell were worth $609,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Lazard Asset Management LLC grew its position in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after acquiring an additional 737,536 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Omnicell in the 4th quarter valued at about $30,637,000. Dimensional Fund Advisors LP grew its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after buying an additional 377,883 shares during the last quarter. Finally, Oberweis Asset Management Inc. bought a new position in shares of Omnicell during the fourth quarter worth approximately $14,834,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Piper Sandler reiterated an “overweight” rating on shares of Omnicell in a research note on Friday, May 23rd. JPMorgan Chase & Co. lowered their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Benchmark decreased their price objective on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $37.00 price target (up previously from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Finally, Wall Street Zen upgraded Omnicell from a “hold” rating to a “buy” rating in a research note on Tuesday, May 20th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Omnicell Stock Down 0.8%

NASDAQ:OMCL opened at $28.03 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23. The firm has a market capitalization of $1.31 billion, a P/E ratio of 60.94 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.75. The company’s fifty day moving average price is $29.45 and its 200-day moving average price is $36.43.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.